JANUARY 19, 2021

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19

Read the Press Release

Other Press Releases

Biophytis SA announces that it participated in the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR), held from March 10 to 12, 2026 in Washington, DC (United…

Read more

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and…

Read more

Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription…

Read more

Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.

Read more

Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia…

Read more

Biophytis announces its participation in two leading healthcare and investment events in January 2026.

Read more